Evidence map›Paper›PMID 40530118›Full record

ArticleTranslational cancer research2025

The prognostic and immune significance of fibronectin type III domain-containing 1 gene in pan-cancer and its relationship with proliferation and migration of stomach adenocarcinoma.

Minying Deng, Wen Huang, Rongkui Luo, Huimei Wang, Zixiang Yu, Benting Ma, Lei Xu, Xiaolei Zhang, Jieakesu Su, Chen Xu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Minying Deng *Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Wen Huang *Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Rongkui Luo *Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Huimei WangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zixiang YuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Benting MaDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Lei XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaolei ZhangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jieakesu SuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chen XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yingyong HouDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Fibronectin type III domain containing 1 (FNDC1) exhibits emerging roles in tumorigenesis, yet its pan-cancer implications and mechanistic contributions to stomach adenocarcinoma (STAD) remain underexplored. This study systematically evaluates FNDC1's prognostic relevance, immune interactions, and functional impact in STAD. Methods: Multi-omics analyses integrated FNDC1 expression, mutation profiles, and immune associations across 33 cancers using The Cancer Genome Atlas (TCGA) data. Immunohistochemistry assessed FNDC1, mismatch repair (MMR) protein, and human epidermal growth factor receptor 2 (HER2), and clinicopathological information was collected for statistical analysis. Finally, we conducted in vitro experiments to assess the effects of FNDC1 knockdown on STAD. Results: In various cancers, the main genetic alterations of Conclusions: FNDC1 is highly expressed in various tumor tissues and may serve as a potential prognostic biomarker and immunotherapy target in cancer. It plays a crucial role in proliferation, migration and invasion of STAD.

Indexed as

biomarkerFibronectin type III domain containing 1 (FNDC1)pan-cancer analysisstomach adenocarcinoma (STAD)

Identifiers

PMID40530118
PMCPMC12170108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.